Developer docs
API playgroundTry for free, no card

Search company profiles

DyNAbind

Full company profile

uuid00093cp

Namestring
DyNAbind
Legal namestring
DyNAbind GmbH
Websiteurl
dynabind.com
Company typeenum
Private
Founded yearint
2017
Descriptiontext

DyNAbind GmbH is a privately held biotechnology company founded in 2017 and headquartered in Dresden, Germany. The company develops next-generation DNA-Encoded Library (DEL) technology for early-stage drug discovery, serving pharmaceutical companies, biotech firms, and academic research groups seeking small molecule binders against challenging targets including membrane proteins, protein-protein interactions, and 14-3-3 protein complexes. DyNAbind employs between 1 and 10 people and operates from a ~160 m2 laboratory and office facility in the BioInnovation Centre.

The company's core technology is built on three patented innovations: (i) Dynamic Libraries, a dual-DNA presentation architecture that continuously generates new structures during screening and delivers over 30-fold improved signal-to-noise ratios; (ii) the Path-Coding Algorithm, an informatic pipeline with built-in error proofing that reduces false positives and false negatives and increases usable sequences by over 37%; and (iii) the Binding Profiler system, an on-DNA biosensor technology that validates hits without resynthesis by returning kinetic data (on-rates, off-rates, dissociation constants). Together these components support a library collection exceeding 125 million fragment and small molecule structures and underwrite the company's positioning around hitting traditionally undruggable targets.

DyNAbind generates revenue through two streams: customized DEL screening campaigns sold directly to enterprise partners (fees project-based and not publicly disclosed) and DEL research-use kits containing over 370,000 fragment pairs distributed exclusively through MilliporeSigma. Go-to-market relies on industry conference participation (BioEurope, Swiss Biotech Day, BioJapan, EFMC ISMC, BioVaria), joint webinars with technology partners, and direct partnering outreach. Notable collaborations include AstraZeneca, Galapagos NV, Almirall, Heptares Therapeutics, OMass Therapeutics, Confo Therapeutics, Salipro Biotech, CEITEC, Northwestern University, University of Edinburgh, and Columbia University. The company received an EXIST Forschungstransfer grant from the German federal government in 2015 and closed a venture funding round in 2019 with European investors including HTGF, TGFS, and TUDAG.

Short descriptiontext

DyNAbind is a Dresden-based biotech company that develops proprietary DNA-Encoded Library technology for drug discovery, offering custom DEL screening campaigns and research-use kits to pharmaceutical, biotech, and academic customers seeking small molecule binders against challenging targets.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersDresden, Germany
HQ citystring
Dresden
HQ countrystring
Germany
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
DNA-encoded library, drug discovery services, hit identification, fragment-based screening, medicinal chemistry
Industry3 codes
PRIMARYHLAAAIAL
Library & Diversity Generation Platforms (display libraries, DNA-encoded libraries for biologics, variant libraries)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAIALAA
Drug Discovery (Target ID/Validation & Hit Discovery)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
SECONDARYHLAAAIAE
AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Scientific Research and Development Services5417
SIC code1 code
  • Services-Commercial Physical & Biological Research8731
Product category
Drug Discovery Services
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1DEL Screening Services
TypeProfessional Services
Description

Customized DNA-Encoded Library screening campaigns tailored to partner drug discovery projects, including campaign design, deep analysis, and hit validation services.

dynabind.com
2DEL Research Kits
TypeOne Time License
Description

Research-use DEL kits sold through distributor MilliporeSigma, containing custom-built libraries with over 370,000 fragment pairs plus access to online data analysis portal.

dynabind.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Personnel, Technology or R&D, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

DyNAbind develops and commercializes next-generation DNA-Encoded Library (DEL) technologies for drug discovery. Its core offerings include the Dynamic Library Platform with a patented dual-DNA presentation architecture, the Path-Coding Algorithm for error-proofed sequencing analysis, and the Binding Profiler on-DNA biosensor for kinetic hit validation. The company sells research-use DEL kits and performs customized DEL screening campaigns for pharmaceutical and academic partners.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Over 30-fold improved signal-to-noise ratios
+2 more records
Product overview1 text field

DyNAbind offers a next-generation platform of DNA-Encoded Library (DEL) technologies for drug discovery. The core offerings consist of the Dynamic Library Platform with dual-DNA presentation architecture, the Path-Coding Algorithm for data analysis, and the Binding Profiler Validation system. These are complemented by DEL research kits distributed through MilliporeSigma and full-service DNA-Encoded Library screening campaigns. The platform combines fragment-based drug discovery principles with DEL technology to deliver higher quality, more relevant medicinal chemistry starting points.

Product and service2 records
1DNA-Encoded Library Screening Campaigns
CategoryDrug discovery services
Description

Customized drug discovery campaigns for pharmaceutical companies, biotech firms, and academic institutions, including campaign design, deep sequencing analysis, and kinetic hit validation services tailored to partner-specific targets.

2DEL Research Kits
CategoryResearch reagents
Description

Research-use DNA-encoded library kits containing multiple aliquots of a custom-built library with over 370,000 fragment pairs plus access to an online data analysis portal, sold exclusively through MilliporeSigma for DIY researchers and academic groups.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership13 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-06-30
Description

Collaboration combining Salipro's proprietary platform technology for membrane proteins with DyNAbind's Dynamic Library DEL technology to enable screening on difficult membrane protein targets like GPCRs, SLC transporters, and Ion Channels. Successfully identified small molecule binders confirmed via surface plasmon resonance.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-06-30
Description

Collaborative research partner in Nature Scientific Reports publication on DEL screening for membrane proteins. Partnered with Salipro Biotech, DyNAbind, and University of Copenhagen using Pannexin 1 channel as model system.

Strategic tierSupportingTypeTechnology or IntegrationAnnounced on2022-04-04
Description

Joint scientific collaboration combining DyNAbind's DEL screening with Pharmacelera's AI and 3D molecular descriptors for improved data post-processing and hit identification from DEL data.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2020-06-09
Description

Long-term framework collaboration agreement for compound screening using DEL technologies for various indications including inflammation and fibrosis. Part of Galapagos' portfolio of clinical-stage first-in-class medicines.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2020-05-18
Description

Collaboration for compound screening using DyNAbind's proprietary DEL technology to discover novel drug candidates for treating dermatological inflammation conditions.

6University of Edinburgh
Strategic tierSupportingTypeStrategic or Co-development PartnerAnnounced on2020-04-27
Description

Collaboration with Centres for Cardiovascular Science and Inflammation Research to discover novel fragment- and small molecule-based drug candidates for treatment of cystic fibrosis.

dynabind.com
Strategic tierSupportingTypeStrategic or Co-development PartnerAnnounced on2019-01-29
Description

Collaboration with Professor Peter Penzes and Center for Autism and Neurodevelopment to discover novel drug candidates for neurodegenerative diseases.

8Heptares Therapeutics
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2018-11-07
Description

Collaboration to find new drug candidates for GPCR targets. Combines DyNAbind's DEL technology with Heptares' membrane protein expertise to tackle historically difficult-to-drug membrane-bound proteins.

dynabind.com
9CEITEC
Strategic tierSupportingTypeStrategic or Co-development PartnerAnnounced on2018-05-30
Description

Strategic alliance for discovery and development of drug candidates targeting human 14-3-3 protein complexes for cancer and neurodegenerative diseases based on research from Dr. Jozef Hritz's labs.

dynabind.com
10MilliporeSigma
Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

Exclusive distributor for DyNAbind's research-use DEL kits containing over 370,000 fragment pairs plus online data analysis portal access. Makes DEL technology accessible to DIY researchers and academic groups.

dynabind.com
Strategic tierSupportingTypeStrategic or Co-development Partner
Description

Drug discovery collaboration combining DyNAbind's DEL technologies with Confo Therapeutics' capabilities.

Strategic tierSupportingTypeStrategic or Co-development Partner
Description

Drug discovery collaboration with Columbia University researchers.

Strategic tierSupportingTypeStrategic or Co-development Partner
Description

Collaboration agreement for drug discovery utilizing DyNAbind's DEL platform.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

X-Chem is one of the largest independent DNA-Encoded Library platforms offering custom DEL screening and a library of over 200 billion compounds. Directly comparable to DyNAbind as a fee-for-service DEL provider to pharma and biotech.

TypeDirect peer
Description

HitGen operates DEL screening services and a DEL-based drug discovery platform (DEL+DNA-tagged library of billions of compounds). Directly comparable as a DEL service and library provider competing for the same pharma screening contracts.

TypeDirect peer
Description

Philochem is a Switzerland-based DEL technology company offering DEL screening services and proprietary libraries. Directly comparable in size, geographic region (DACH + EU), and DEL service offering.

TypeDirect peer
Description

Vipergen provides DEL-based screening services including on-DNA kinetic and binder-confirmation assays. Comparable to DyNAbind as a specialized DEL service provider targeting difficult drug targets.

TypeBroad incumbent
Description

WuXi AppTec offers DNA-Encoded Library screening among its broader CRO/preclinical services. A large incumbent competing on scale and pricing; comparable technology within a much broader service portfolio.

TypeBroad incumbent
Description

Charles River provides drug discovery services including DEL-style screening through its early-discovery portfolio. Comparable as a CRO competitor that pharma may route screening budgets to.

TypeDirect peer
Description

Edelris is a French CRO specializing in DEL technology (KeymicalTM library) and fragment-based discovery. Closely comparable to DyNAbind as a European DEL service provider of similar scale.

8Nuevolution (Amgen)
TypeBroad incumbent
Description

Originally an independent DEL platform (acquired by Amgen in 2015), Nuevolution's Chemetics platform exemplifies the in-house DEL path large pharma have chosen. Comparable as a DEL technology benchmark and competitive alternative if pharma insources.

TypeEmerging player
Description

Pharmacelera provides AI/3D molecular descriptor tools for DEL and virtual screening data interpretation. Comparable to DyNAbind as a collaborator/adjacent player in the AI-enabled DEL data analysis stack.

TypeEmerging player
Description

Salipro develops a proprietary membrane-protein platform enabling DEL screening on GPCRs, ion channels, and SLC transporters. Comparable as a partner and adjacent technology enabling the same difficult-target workflows DyNAbind addresses.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers8 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors3 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

DyNAbind

Drug Discovery Servicesdynabind.com

DyNAbind is a Dresden-based biotech company that develops proprietary DNA-Encoded Library technology for drug discovery, offering custom DEL screening campaigns and research-use kits to pharmaceutical, biotech, and academic customers seeking small molecule binders against challenging targets.

What DyNAbind does

DyNAbind GmbH is a privately held biotechnology company founded in 2017 and headquartered in Dresden, Germany. The company develops next-generation DNA-Encoded Library (DEL) technology for early-stage drug discovery, serving pharmaceutical companies, biotech firms, and academic research groups seeking small molecule binders against challenging targets including membrane proteins, protein-protein interactions, and 14-3-3 protein complexes. DyNAbind employs between 1 and 10 people and operates from a ~160 m2 laboratory and office facility in the BioInnovation Centre.

The company's core technology is built on three patented innovations: (i) Dynamic Libraries, a dual-DNA presentation architecture that continuously generates new structures during screening and delivers over 30-fold improved signal-to-noise ratios; (ii) the Path-Coding Algorithm, an informatic pipeline with built-in error proofing that reduces false positives and false negatives and increases usable sequences by over 37%; and (iii) the Binding Profiler system, an on-DNA biosensor technology that validates hits without resynthesis by returning kinetic data (on-rates, off-rates, dissociation constants). Together these components support a library collection exceeding 125 million fragment and small molecule structures and underwrite the company's positioning around hitting traditionally undruggable targets.

DyNAbind generates revenue through two streams: customized DEL screening campaigns sold directly to enterprise partners (fees project-based and not publicly disclosed) and DEL research-use kits containing over 370,000 fragment pairs distributed exclusively through MilliporeSigma. Go-to-market relies on industry conference participation (BioEurope, Swiss Biotech Day, BioJapan, EFMC ISMC, BioVaria), joint webinars with technology partners, and direct partnering outreach. Notable collaborations include AstraZeneca, Galapagos NV, Almirall, Heptares Therapeutics, OMass Therapeutics, Confo Therapeutics, Salipro Biotech, CEITEC, Northwestern University, University of Edinburgh, and Columbia University. The company received an EXIST Forschungstransfer grant from the German federal government in 2015 and closed a venture funding round in 2019 with European investors including HTGF, TGFS, and TUDAG.

DyNAbind firmographics

Firmographics
Name
DyNAbind
Legal name
DyNAbind GmbH
Website
https://dynabind.com
Company type
Private
Founded year
2017
Operating status
Operating
Headcount range
1–10 employees
Short description
DyNAbind is a Dresden-based biotech company that develops proprietary DNA-Encoded Library technology for drug discovery, offering custom DEL screening campaigns and research-use kits to pharmaceutical, biotech, and academic customers seeking small molecule binders against challenging targets.
Ownership category
akta.pro rank

DyNAbind industry classification

Industry
Product category
Drug Discovery Services
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
SIC
Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAAAIAL
Library & Diversity Generation Platforms (display libraries, DNA-encoded libraries for biologics, variant libraries)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAIALAA
Drug Discovery (Target ID/Validation & Hit Discovery)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
SECONDARYHLAAAIAE
AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)

Keywords

  • DNA-encoded library
  • Drug discovery services
  • Hit identification
  • Fragment-based screening
  • Medicinal chemistry

Where DyNAbind is headquartered

Location

Headquarters

HQ city
Dresden
HQ country
Germany
HQ region
Europe

Offices1 record

Markets served

DyNAbind business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales

Revenue model

  1. DEL Screening Services: Customized DNA-Encoded Library screening campaigns tailored to partner drug discovery projects, including campaign design, deep analysis, and hit validation services.
  2. DEL Research Kits: Research-use DEL kits sold through distributor MilliporeSigma, containing custom-built libraries with over 370,000 fragment pairs plus access to online data analysis portal.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels4 records

DyNAbind product offering

Product offering

Core offering

DyNAbind develops and commercializes next-generation DNA-Encoded Library (DEL) technologies for drug discovery. Its core offerings include the Dynamic Library Platform with a patented dual-DNA presentation architecture, the Path-Coding Algorithm for error-proofed sequencing analysis, and the Binding Profiler on-DNA biosensor for kinetic hit validation. The company sells research-use DEL kits and performs customized DEL screening campaigns for pharmaceutical and academic partners.

Product overview

DyNAbind offers a next-generation platform of DNA-Encoded Library (DEL) technologies for drug discovery. The core offerings consist of the Dynamic Library Platform with dual-DNA presentation architecture, the Path-Coding Algorithm for data analysis, and the Binding Profiler Validation system. These are complemented by DEL research kits distributed through MilliporeSigma and full-service DNA-Encoded Library screening campaigns. The platform combines fragment-based drug discovery principles with DEL technology to deliver higher quality, more relevant medicinal chemistry starting points.

Differentiator

Problem solved

Functional benefit

Products and services

  • DNA-Encoded Library Screening Campaigns Customized drug discovery campaigns for pharmaceutical companies, biotech firms, and academic institutions, including campaign design, deep sequencing analysis, and kinetic hit validation services tailored to partner-specific targets.
  • DEL Research Kits Research-use DNA-encoded library kits containing multiple aliquots of a custom-built library with over 370,000 fragment pairs plus access to an online data analysis portal, sold exclusively through MilliporeSigma for DIY researchers and academic groups.

Quantifiable outcome

  • Over 30-fold improved signal-to-noise ratios
  • +2 more outcomes

Companies that use DyNAbind

Customer profile

Named customers8 records

Segments3 records

Ideal customer profiles3 records

DyNAbind technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

DyNAbind partnerships and signals

Strategic signal

Partnerships

13 partnerships are on record, tiered core and supporting.

  • Salipro Biotech ABcoreStrategic or Co-development Partner · 30 June 2026Collaboration combining Salipro's proprietary platform technology for membrane proteins with DyNAbind's Dynamic Library DEL technology to enable screening on difficult membrane protein targets like GPCRs, SLC transporters, and Ion Channels. Successfully identified small molecule binders confirmed via surface plasmon resonance.
  • AstraZenecacoreStrategic or Co-development Partner · 30 June 2026Collaborative research partner in Nature Scientific Reports publication on DEL screening for membrane proteins. Partnered with Salipro Biotech, DyNAbind, and University of Copenhagen using Pannexin 1 channel as model system.
  • PharmacelerasupportingTechnology or Integration · 4 April 2022Joint scientific collaboration combining DyNAbind's DEL screening with Pharmacelera's AI and 3D molecular descriptors for improved data post-processing and hit identification from DEL data.
  • Galapagos NVcoreStrategic or Co-development Partner · 9 June 2020Long-term framework collaboration agreement for compound screening using DEL technologies for various indications including inflammation and fibrosis. Part of Galapagos' portfolio of clinical-stage first-in-class medicines.
  • AlmirallcoreStrategic or Co-development Partner · 18 May 2020Collaboration for compound screening using DyNAbind's proprietary DEL technology to discover novel drug candidates for treating dermatological inflammation conditions.
  • University of EdinburghsupportingStrategic or Co-development Partner · 27 April 2020Collaboration with Centres for Cardiovascular Science and Inflammation Research to discover novel fragment- and small molecule-based drug candidates for treatment of cystic fibrosis.
  • Northwestern UniversitysupportingStrategic or Co-development Partner · 29 January 2019Collaboration with Professor Peter Penzes and Center for Autism and Neurodevelopment to discover novel drug candidates for neurodegenerative diseases.
  • Heptares TherapeuticscoreStrategic or Co-development Partner · 7 November 2018Collaboration to find new drug candidates for GPCR targets. Combines DyNAbind's DEL technology with Heptares' membrane protein expertise to tackle historically difficult-to-drug membrane-bound proteins.
  • CEITECsupportingStrategic or Co-development Partner · 30 May 2018Strategic alliance for discovery and development of drug candidates targeting human 14-3-3 protein complexes for cancer and neurodegenerative diseases based on research from Dr. Jozef Hritz's labs.
  • MilliporeSigmacoreChannel Partner/ Reseller/ DistributorExclusive distributor for DyNAbind's research-use DEL kits containing over 370,000 fragment pairs plus online data analysis portal access. Makes DEL technology accessible to DIY researchers and academic groups.
  • Confo TherapeuticssupportingStrategic or Co-development PartnerDrug discovery collaboration combining DyNAbind's DEL technologies with Confo Therapeutics' capabilities.
  • Columbia UniversitysupportingStrategic or Co-development PartnerDrug discovery collaboration with Columbia University researchers.
  • OMass TherapeuticssupportingStrategic or Co-development PartnerCollaboration agreement for drug discovery utilizing DyNAbind's DEL platform.

Scale indicators4 records

Recent moves7 records

Expansion highlights6 records

DyNAbind competitors and assessment

Company assessment

Direct peers

  • X-Chem Pharmaceuticals: X-Chem is one of the largest independent DNA-Encoded Library platforms offering custom DEL screening and a library of over 200 billion compounds. Directly comparable to DyNAbind as a fee-for-service DEL provider to pharma and biotech.
  • HitGen: HitGen operates DEL screening services and a DEL-based drug discovery platform (DEL+DNA-tagged library of billions of compounds). Directly comparable as a DEL service and library provider competing for the same pharma screening contracts.
  • Philochem: Philochem is a Switzerland-based DEL technology company offering DEL screening services and proprietary libraries. Directly comparable in size, geographic region (DACH + EU), and DEL service offering.
  • Vipergen: Vipergen provides DEL-based screening services including on-DNA kinetic and binder-confirmation assays. Comparable to DyNAbind as a specialized DEL service provider targeting difficult drug targets.
  • Edelris: Edelris is a French CRO specializing in DEL technology (KeymicalTM library) and fragment-based discovery. Closely comparable to DyNAbind as a European DEL service provider of similar scale.

Broad incumbents

  • WuXi AppTec (DEL platform): WuXi AppTec offers DNA-Encoded Library screening among its broader CRO/preclinical services. A large incumbent competing on scale and pricing; comparable technology within a much broader service portfolio.
  • Charles River Laboratories: Charles River provides drug discovery services including DEL-style screening through its early-discovery portfolio. Comparable as a CRO competitor that pharma may route screening budgets to.
  • Nuevolution (Amgen): Originally an independent DEL platform (acquired by Amgen in 2015), Nuevolution's Chemetics platform exemplifies the in-house DEL path large pharma have chosen. Comparable as a DEL technology benchmark and competitive alternative if pharma insources.

Emerging players

  • Pharmacelera: Pharmacelera provides AI/3D molecular descriptor tools for DEL and virtual screening data interpretation. Comparable to DyNAbind as a collaborator/adjacent player in the AI-enabled DEL data analysis stack.
  • Salipro Biotech AB: Salipro develops a proprietary membrane-protein platform enabling DEL screening on GPCRs, ion channels, and SLC transporters. Comparable as a partner and adjacent technology enabling the same difficult-target workflows DyNAbind addresses.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

DyNAbind social profiles

Digital presence

DyNAbind financial estimates

Financial estimate

Revenue estimate

Valuation estimate

DyNAbind leadership team

Management profile

Number of profiles

Profiles4 records

DyNAbind funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

DyNAbind M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about DyNAbind

What does DyNAbind do?

DyNAbind develops and commercializes next-generation DNA-Encoded Library (DEL) technologies for drug discovery. Its core offerings include the Dynamic Library Platform with a patented dual-DNA presentation architecture, the Path-Coding Algorithm for error-proofed sequencing analysis, and the Binding Profiler on-DNA biosensor for kinetic hit validation. The company sells research-use DEL kits and performs customized DEL screening campaigns for pharmaceutical and academic partners.

Is DyNAbind a public or private company?

DyNAbind is a private company. It is classified as venture growth investor backed and is currently operating.

When was DyNAbind founded?

DyNAbind was founded in 2017. It employs 1 to 10 people.

Where is DyNAbind based?

DyNAbind is headquartered in Dresden, Germany, in the Europe region.

How does DyNAbind make money?

Two revenue lines are on record. DEL Screening Services are the primary driver. The others are DEL Research Kits.

Who are DyNAbind's main competitors?

Direct peers on record are X-Chem Pharmaceuticals, HitGen, Philochem, Vipergen and Edelris. Broad incumbents are WuXi AppTec (DEL platform), Charles River Laboratories and Nuevolution (Amgen). Emerging players are Pharmacelera and Salipro Biotech AB.

Does DyNAbind have an API?

No public API is recorded for DyNAbind.

What industry is DyNAbind in?

DyNAbind's product category is Drug Discovery Services. Its primary akta.pro industry code is HLAAAIAL, Library & Diversity Generation Platforms (display libraries, DNA-encoded libraries for biologics, variant libraries), with a secondary code of HLAIALAA, Drug Discovery (Target ID/Validation & Hit Discovery). Its NAICS code is 541714 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
BioSpaceSalipro Biotech Announces Publication in Nature Scientific Reports on Expanding DEL Screening to Membrane ProteinsSalipro Biotech announced a study in Nature Scientific Reports demonstrating DNA-encoded library screening on membrane proteins using its Salipro platform. The study, with collaborators from AstraZeneca, DyNAbind, and the University of Copenhagen, screened millions of compounds against Pannexin 1 and identified novel binders validated by structural and functional assays. The work establishes a proof-of-concept for applying DEL screening to complex membrane proteins.PharmaceleraDyNAbind and Pharmacelera collaborationDyNAbind and Pharmacelera announced a joint scientific collaboration to combine DNA-Encoded Libraries (DEL) with Artificial Intelligence for drug discovery. The partnership aims to address data management challenges in DEL screenings by using AI tools to convert binders into synthesizable hits, thereby enabling the identification of novel chemical scaffolds. This collaboration leverages DyNAbind's screening capabilities and Pharmacelera's computational expertise to support de novo drug design.FinSMEsDyNAbind Raises Seed FundingDyNAbind, a Dresden-based drug discovery startup, raised an undisclosed seed round from High-Tech Gründerfonds, TGFS, and TUDAG. The funds will build a larger lab and expand its team. The company's DNA-encoded library platform partners with pharma and academia, including SoseiHeptares and Merck KGaA.PR NewswireSosei Enters Collaboration to Combine Pioneering DNA Technologies With StaR® Technology to Accelerate New Drug DiscoverySosei Group Corporation's wholly owned subsidiary Heptares Therapeutics has entered a collaboration agreement with Germany-based DyNAbind GmbH to combine next-generation DNA-encoded library technologies with its proprietary StaR® proteins for drug discovery. The partnership aims to generate and optimize selective small molecule drug candidates for multiple GPCR targets, including historically hard-to-drug targets, at no material financial cost to Sosei. Sosei retains full rights to advance the most promising compounds into its discovery and development pipeline.